At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?
Lilly has been active on the M&A front with a series of biotech acquisitions totaling up to more than $20 billion in 2026 to date What moves is the company making?
European policymakers reached a provisional agreement on the Critical Medicines Act, designed to strengthen the EU’s pharma manufacturing base. What is next?
Dr. Marty Makary stepped down this week as FDA Commissioner, marking the latest leadership change at the agency. What may be the policy implications for such a move?
How are small-molecule drugs faring in new drug approvals by FDA and among potential blockbuster contenders? DCAT Value Chain Insights takes an inside look.
The success of the GLP-1 agonists and related follow-on drugs has renewed interest in peptide-based drugs. Industry experts share their perspectives on the latest in peptide synthesis.
As part of a broader initiative to make its inspectional resources efficient, FDA has launched a pilot for one-day inspectional assessments. What does the new program involve?
